Last reviewed · How we verify
NCT04298112
PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment
trial testing PSMA PET/CT in Prostatic Neoplasms in 300 participants. Completed in 1 May 2023.
1 May 2023
Quick facts
| Lead sponsor | Norwegian University of Science and Technology |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 May 2020 |
| Primary completion | 1 May 2023 |
| Estimated completion | 1 May 2023 |
| Sites | 3 locations across Norway |
Drugs / interventions tested
- PSMA PET/CT
- PSMA PET/MR
Conditions studied
- Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Sponsor
Norwegian University of Science and Technology
Who can join
18 and older, male only, with Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Approximately one third of prostate cancer patients experience biochemical relapse following initial radical prostatectomy or curative radiotherapy. To determine further treatment, it is of utmost importance to accurately differentiate local and regional recurrence from distant metastatic disease. Unfortunately, the currently used medical imaging methods (MRI and bone scan) lack sensitivity for detection of nodal and skeletal metastases, which can lead to over-treatment of patients with occult metastatic disease. PET imaging with prostate specific membrane antigen (PSMA)-ligands has shown a promising potential for improving the detection accuracy in recurrent prostate cancer, especially when combined with the excellent soft-tissue contrast of MRI. However, evidence is mostly based on retrospective single center studies so far, including patients with a wide variety of PSA levels. Improving the sensitivity for detection of metastatic disease is a crucial step in reducing over-treatment of prostate cancer patients with biochemical relapse following radical treatment. The purpose of this prospective multi-center study is to standardize PSMA PET/CT and PET/MRI imaging across three university hospitals in Norway, and investigate its merit for detection of recurrent prostate cancer. The long-term overall goal is offering prostate cancer patients a more personalized treatment plan aiming to improve the chances of survival and quality of life.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04298112
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PSMA PET/CT
Trials testing the same drug.
- NCT06387238 — Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients Wit · NA · not yet recruiting
- NCT06209853 — Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient · recruiting
- NCT04745871 — Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastas · NA · recruiting
- NCT03841760 — SUV on PSMA PET/CT in Non-Prostate Tumors · Phase 2 · terminated
- NCT03938766 — Upregulation of PSMA Receptors After Androgen Deprivation Therapy on PSMA PET/CT Imaging in Prostate Cancer · NA · completed
Other recruiting trials for Prostatic Neoplasms
Currently open trials in the same condition.
- NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
- NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
- NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
- NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
- NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting
Other Norwegian University of Science and Technology trials
Trials by the same sponsor.
- NCT07521891 — Socket-leg Interface Movements in Transtibial Amputees · NA · not yet recruiting
- NCT07463001 — Optimization and Testing Effectiveness of a Collaborative Intervention for School Attendance Problems in Norwegian Munic · NA · not yet recruiting
- NCT07422597 — Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prost · NA · recruiting
- NCT06558851 — The Effect of Systematic Endurance Training in Treatment of Women With Lipedema · NA · active not recruiting
- NCT06893874 — A Pragmatic Trial of Machine Prescription for Migraine · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04298112 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Norwegian University of Science and Technology
- Last refreshed: 15 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04298112.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing